Skip to content

US · AVXL · BIOTECHNOLOGY

Anavex Life Sciences Corp. (AVXL) intrinsic value and stock valuation

$0.59as of 2026-11-21 · Mkt cap 309.52M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Anavex Life Sciences Corp. DCF and intrinsic value

InvestorsCraft values AVXL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVXL’s statements →

Anavex Life Sciences Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10019 anavex.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-46.38M
20112025
Free cash flow
-$-39.04M
20112025
Total equity
$94.9M+28.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-51.41M-$-52.88M-$-55.76M-$-50.99M-$-42M
Net income-$-46.38M-$-43M-$-47.51M-$-47.98M-$-37.91M
EPSd-$-543.79K-$-515.16K-$-595.44K-$-623.85K-$-543.12K
Operating cash flow-$-39.04M-$-30.81M-$-27.79M-$-24.24M-$-30.38M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-39.04M-$-30.81M-$-27.79M-$-24.24M-$-30.38M
Total assets$103.8M$135.6M$154.4M$152.7M$161.6M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-102.58M-$-132.19M-$-151.02M-$-149.16M-$-152.11M
Total equity$94.9M$120.3M$141.9M$142.5M$150.8M
Cash and short-term investments$102.6M$132.2M$151M$149.2M$152.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$37.6M$41.8M$43.7M$37.9M$33M
Selling, general and administrative expenses$13.8M$11M$12.1M$13.1M$9.02M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$51.4M$52.9M$55.8M$51M$42M
Cost and expenses$51.4M$52.9M$55.8M$51M$42M
Interest income$4.68M$7.32M$6.52M$950K$30K
Interest expense$0.00$0.00$960K$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-46.38M-$-43M-$-46.54M-$-47.62M-$-37.64M
Operating income-$-51.41M-$-52.88M-$-55.76M-$-50.99M-$-42M
Total other income/expenses, net$5.03M$9.88M$8.26M$3.37M$4.36M
Income before tax-$-46.38M-$-43M-$-47.51M-$-47.62M-$-37.64M
Income tax expense$0.00$0.00$0.00$360K$270K
Net income-$-46.38M-$-43M-$-47.51M-$-47.98M-$-37.91M
Weighted average shares outstanding$85.3M$83.5M$79.8M$76.9M$69.8M
Weighted average diluted shares outstanding$85.3M$83.5M$79.8M$76.9M$69.8M
Balance sheet
20252024202320222021
Cash and short-term investments$102.6M$132.2M$151M$149.2M$152.1M
Net receivables$810K$2.45M$2.71M$3.19M$9.14M
Inventory$0.00$0.00$0.00$0.00$20K
Total current assets$103.8M$135.6M$154.4M$152.7M$161.6M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$3.36M$3.55B$20K
Total assets$103.8M$135.6M$154.4M$152.7M$161.6M
Accounts payable$4.25M$9.63M$4.32M$3.82M$4.74M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$810K$840K$920K$440K$440K
Total current liabilities$8.95M$15.3M$12.5M$10.2M$10.8M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$8.95M$15.3M$12.5M$10.2M$10.8M
Common stock$90K$90K$80K$80K$80K
Retained earnings-$-382.45M-$-336.07M-$-293.07M-$-245.56M-$-197.59M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$94.9M$120.3M$141.9M$142.5M$150.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-102.58M-$-132.19M-$-151.02M-$-149.16M-$-152.11M
Cash flow statement
20252024202320222021
Net income-$-46.38M-$-43M-$-47.51M-$-47.98M-$-37.91M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$11.6M$9.44M$16.4M$18.4M$8.23M
Change in working capital-$-4.22M$2.75M$2.5M$5.36M-$-710K
Accounts receivable$1.64M$260K$480K$5.94M-$-4.29M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.38M$5.3M$500K-$-910K$750K
Net cash provided by operating activities-$-39.04M-$-30.81M-$-27.79M-$-24.24M-$-30.38M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$12.1M$12M$29.7M$22M$153.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.43M$12M$29.7M$21.3M$153.2M
Net change in cash-$-29.61M-$-18.84M$1.87M-$-2.95M$122.9M
Cash at end of period$102.6M$132.2M$151M$149.2M$152.1M
Operating cash flow-$-39.04M-$-30.81M-$-27.79M-$-24.24M-$-30.38M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-39.04M-$-30.81M-$-27.79M-$-24.24M-$-30.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Anavex Life Sciences Corp.

        Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.

        CEO
        Terrie Kellmeyer
        Employees
        34
        Beta
        1.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Anavex Life Sciences Corp. (AVXL)?

        InvestorsCraft does not currently publish an intrinsic value for AVXL. How the IC value is calculated.

        Is AVXL undervalued?

        InvestorsCraft does not publish an undervaluation signal for AVXL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.